Biothera thinks its Imprime PGG beta-glucan, a soluble carbohydrate, could be combined with complement-fixing MAbs to improve their efficacy compared to the MAbs alone in some cancers.

Last week, the company's scientists published preclinical data in Cancer Research demonstrating significantly increased survival in murine xenograft models of non-small cell lung cancer (NSCLC) given Erbitux cetuximab in combination with the yeast-derived beta-glucan compared with mice given Erbitux alone. Animals given